水素水14日間摂取がロングCOVID患者の疲労軽減に与える影響：パイロット単盲検無作為化対照試験
This pilot single-blind randomized controlled trial enrolled 32 Long-COVID patients (16 per group) to evaluate 14 consecutive days of hydrogen-rich water (HRW) versus placebo water. HRW significantly reduced Fatigue Severity Scale scores (p=0.046, Cohen's d=0.696) and improved Six-Minute Walk Test distance (p<0.001, d=1.010), 30-second Chair Stand Test performance (p=0.002, d=1.190), and Pittsburgh Sleep Quality Index scores (p=0.012, d=1.274). No significant differences were observed for the Modified Medical Research Council Dyspnea Rating Scale (p=0.556) or the Depression Anxiety Stress Scale-21 (p>0.143). These findings suggest that HRW consumption may benefit cardiorespiratory endurance, musculoskeletal function, sleep quality, and fatigue in Long-COVID patients, while dyspnea remains unaffected.
H2's antioxidant and anti-inflammatory properties are proposed to reduce oxidative stress and systemic inflammation associated with Long-COVID, thereby alleviating fatigue and improving physical and sleep-related outcomes.
Hydrogen-rich water is a low-risk delivery route, but the achievable systemic hydrogen dose is bounded. For clinical applications, inhalation is the most efficient route; inhalation, however, carries explosion risk, and concentration matters (empirical LFL of 10% applies to inhalation environments; high-concentration devices are documented in the Consumer Affairs Agency accident database and are not recommended).
See also:
https://h2-papers.org/en/papers/38794767